Inventiva S.A.
Index- P/E- EPS (ttm)-1.37 Insider Own- Shs Outstand42.13M Perf Week16.80%
Market Cap207.70M Forward P/E- EPS next Y- Insider Trans- Shs Float42.13M Perf Month-3.31%
Income- PEG- EPS next Q- Inst Own23.94% Short Float / Ratio0.35% / 2.70 Perf Quarter0.69%
Sales9.74M P/S21.31 EPS this Y- Inst Trans- Short Interest0.15M Perf Half Y-51.60%
Book/sh2.29 P/B1.91 EPS next Y- ROA- Target Price16.02 Perf Year-66.57%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.49 - 14.33 Perf YTD-67.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-69.43% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low25.42% ATR0.47
Employees109 Current Ratio- Sales Q/Q-11.80% Oper. Margin- RSI (14)49.56 Volatility8.33% 10.31%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.05 Prev Close4.35
ShortableYes LT Debt/Eq- EarningsSep 21 AMC Payout- Avg Volume54.94K Price4.38
Recom- SMA205.03% SMA50-6.92% SMA200-40.79% Volume2,625 Change0.69%
Nov-15-22Downgrade Societe Generale Buy → Sell
Mar-08-21Downgrade Societe Generale Buy → Sell
Aug-05-20Initiated ROTH Capital Buy
Aug-04-20Initiated Stifel Buy $18
Aug-04-20Initiated Guggenheim Buy $26
Nov-28-22 04:00PM
Nov-21-22 04:00PM
Nov-10-22 04:00PM
Oct-31-22 07:58AM
03:00AM Loading…
Oct-21-22 04:00PM
Sep-26-22 01:37PM
Sep-22-22 07:27AM
Sep-21-22 04:40PM
Sep-08-22 09:35AM
Sep-07-22 04:00PM
Jul-28-22 04:00PM
Jul-21-22 12:00PM
04:00PM Loading…
Jul-07-22 04:00PM
Jul-04-22 12:45PM
Jun-16-22 04:00PM
Jun-15-22 09:55AM
Jun-09-22 04:00PM
Jun-07-22 04:00PM
Jun-03-22 04:00PM
May-23-22 04:00PM
May-20-22 04:00PM
May-19-22 04:00PM
May-16-22 04:00PM
Apr-28-22 10:35AM
04:00PM Loading…
Apr-07-22 04:00PM
Apr-05-22 10:45AM
Mar-11-22 04:44PM
Mar-08-22 02:00AM
Mar-07-22 04:27PM
Mar-01-22 04:00PM
Feb-28-22 04:00PM
Feb-23-22 10:00AM
Feb-14-22 04:00PM
Jan-31-22 04:00PM
Jan-20-22 04:00PM
Jan-14-22 02:00AM
Dec-16-21 04:00PM
Dec-06-21 04:00PM
Nov-10-21 04:00PM
Nov-03-21 04:00PM
Oct-29-21 09:29AM
Oct-28-21 07:15AM
Oct-27-21 04:00PM
Oct-18-21 04:00PM
Sep-28-21 04:00PM
Sep-23-21 02:45AM
Sep-22-21 07:01AM
Sep-21-21 04:00PM
Sep-20-21 04:10PM
Sep-16-21 04:00PM
Sep-10-21 09:00AM
Sep-08-21 04:00PM
Aug-30-21 04:00PM
Aug-02-21 05:00PM
Jul-28-21 04:00PM
Jul-22-21 10:00AM
Jun-15-21 04:00PM
Jun-09-21 04:00PM
May-25-21 04:00PM
May-12-21 04:00PM
Apr-26-21 04:00PM
Apr-19-21 04:00PM
Mar-25-21 01:00PM
Mar-15-21 05:00PM
Mar-05-21 11:45AM
Mar-04-21 04:00PM
Feb-25-21 04:00PM
Feb-24-21 04:00PM
Feb-23-21 04:00PM
Feb-11-21 04:00PM
Jan-15-21 11:45AM
Jan-06-21 04:00PM
Jan-05-21 04:00PM
Dec-07-20 11:18PM
Nov-24-20 04:00PM
Nov-12-20 04:00PM
Nov-10-20 04:00PM
Nov-09-20 04:00PM
Nov-05-20 04:00PM
Nov-02-20 04:00PM
Oct-28-20 05:00PM
Oct-19-20 04:00PM
Oct-12-20 04:00PM
Oct-05-20 04:00PM
Sep-24-20 12:15PM
Sep-17-20 06:00AM
Sep-16-20 04:00PM
Sep-09-20 11:45AM
Aug-12-20 11:45AM
Aug-10-20 11:45AM
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.